The Readout Loud

View Top 200 Chart

Back to Rankings Page

Business
**The Readout Loud**

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Latest Episodes:

Episode 58: Democratizing CRISPR, drugging the undruggable, and reading pharma's fine print Apr 18, 2019

Show notes

Who gets to "play God"? Can old technologies learn new tricks? And what does "drug price" even mean?

Episode 57: Trump’s drug pricing foot soldier, Gilead’s uncertain future, & transpacific angst Apr 11, 2019

Show notes

How do you sell lefty ideas to righty politicians? What’s going on at Gilead Sciences? And why are biotech investors freaking out?

Episode 56: Cheaper insulin, the next Juul, and diagnosing disease with sound Apr 04, 2019

Show notes

What if pharma just charged less for drugs? Can speaking three syllables reveal whether you're depressed? And why is Snoop Dogg selling erectile dysfunction pills on TV?

Episode 55: The fate of Bristol-Myers-Celgene, the tragedy of SIDS, and health tech's challenges Mar 28, 2019

Show notes

Why can't investors think for themselves? How do parents cope with inexplicable tragedy? And is tech prepared for the toughest parts of health care?

Episode 54: Another big Alzheimer’s failure, postpartum progress, and Long Island shores Mar 21, 2019

Show notes

Should Alzheimer's researchers just give up on amyloid plaques? What will a new drug mean for new moms with postpartum depression? And which coastal region of Long Island is superior?

Episode 53: How startups stop, the new FDA boss, and Theranos on the big screen Mar 14, 2019

Show notes

Who deserves credit for a new gene therapy? How do you push stop on a startup? And what does MC Hammer have to do with Theranos?

Episode 52: Every conceivable angle of Scott Gottlieb's FDA resignation Mar 07, 2019

Show notes

Why is Scott Gottlieb quitting the FDA? Who will replace him? And what's the proper elastane content of a skinny jean?

Episode 51: CEOs at the Senate, merger mania, and sleuthing startups Feb 28, 2019

Show notes

Is this the age of the big biotech buyout? Is cold brew a business expense? And how do you pronounce "Gonzalez"?

Episode 50: A big scoop on opioid marketing Feb 22, 2019

Show notes

What did an opioid patriarch say under oath? Why did everyone want to know so badly? And how might it shape the conversation around the opioid crisis?

Episode 49: Painkiller racketeering, the limits of genetic tests, and pharma's day on the Hill Feb 21, 2019

Show notes

Is pharma about to have its Big Tobacco moment? Are we overestimating human genetics? And can sales reps rap? We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, Boston Globe reporter Jonathan Saltzman joins us to discuss the case against Insys Therapeutics, the maker of a powerful painkiller now accused of running a nationwide racketeering scheme. Then Dr. Laura Esserman of the University of California, San Francisco, comes on to break down the debate over genetic testing for cancer risk. And then we give you the need-to-know on an upcoming Senate hearing that will see seven pharma executives get grilled on the rising cost of medicines in the U.S.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected